CASSIOPEIA phase III study of Darzalex + Velcade + Thalomid + dexamthasone shows efficacy in multiple myeloma.- Genmab
Part 1 of the CASSIOPEIA phase III study compared the addition of Darzalex (daratumumab), from Genmab, to Velcade (bortezomib), Thalomid (thalidomide), and dexamethasone (D-VTd) induction/consolidation with VTd alone in transplant-eligible patients with newly diagnosed multiple myeloma.